← Back to Search

Potassium Channel Blocker

Amifampridine Phosphate for Myasthenia Gravis

Phase 3
Waitlist Available
Led By Renato Mantegazza, MD
Research Sponsored by Catalyst Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over 21 months
Awards & highlights

Study Summary

This trial will evaluate the long-term safety of a drug that may help people with MuSK-MG, a disease that causes muscle weakness.

Eligible Conditions
  • Myasthenia Gravis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over 21 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and over 21 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

Side effects data

From 2020 Phase 3 trial • 93 Patients • NCT03304054
43%
Paraesthesia oral
40%
Paraesthesia
16%
Nausea
14%
Diarrhoea
13%
Headache
12%
Fatigue
10%
Hypoaesthesia oral
9%
Dizziness
8%
Abdominal pain upper
8%
Dyspepsia
6%
Muscle spasms
6%
Peripheral coldness
6%
Abdominal discomfort
5%
Pain in extremity
5%
Hypoaesthesia
3%
Urinary tract infection
3%
Sensory disturbance
3%
Feeling cold
3%
Vomiting
3%
Asthenia
3%
Nasopharyngitis
3%
Abdominal pain
3%
Back pain
3%
Tinnitus
3%
Dyspnoea
3%
Oropharyngeal pain
2%
Palpitations
2%
Anxiety
2%
Rash maculo-papular
2%
Feeling hot
2%
Ear infection
2%
Sinusitis
2%
Diplopia
2%
Fall
2%
Muscular weakness
2%
Speech disorder
2%
Insomnia
2%
Cough
1%
Myasthenia gravis
1%
Myasthenia gravis crisis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Amifampridine Phosphate
Placebo
Overall

Trial Design

1Treatment groups
Experimental Treatment
Group I: amifampridine phosphateExperimental Treatment1 Intervention
tablets equivalent to 10mg amifampridine, 3 to 4 times per day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amifampridine Phosphate
2019
Completed Phase 3
~170

Find a Location

Who is running the clinical trial?

Catalyst Pharmaceuticals, Inc.Lead Sponsor
13 Previous Clinical Trials
806 Total Patients Enrolled
1 Trials studying Myasthenia Gravis
93 Patients Enrolled for Myasthenia Gravis
Renato Mantegazza, MDPrincipal InvestigatorCarlo Besta Neurological Institute
2 Previous Clinical Trials
148 Total Patients Enrolled
1 Trials studying Myasthenia Gravis
93 Patients Enrolled for Myasthenia Gravis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
2018. "Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03579966.
All > Myasthenia Gravis
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top